의료용 영상용 AI 시장 : 성장, 동향, COVID-19의 영향, 예측(2021-2026년)
AI Market in Medical Imaging - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)
Mordor Intelligence Pvt Ltd
|| 2022년 01월 || 상품코드
| 페이지 정보
|| 2-3일 (영업일 기준)
의료용 영상용 AI 시장 : 성장, 동향, COVID-19의 영향, 예측(2021-2026년)
AI Market in Medical Imaging - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)
|발행일 : 2022년 01월 ||페이지 정보 : 영문
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.
의료용 영상용 AI 시장 규모는 2021-2026년 예측기간 중 30.4%의 CAGR로 성장할 것으로 예상됩니다. 고령 인구 증가는 헬스케어 생태계에 대한 투자 증가와 함께 예측기간 중 시장 전체의 성장에 플러스 영향을 미칠 것으로 예상됩니다. 선진국은 이 인구통계 과제에 직면하고 있으며, 적정 가격으로 첨단 헬스케어 시스템을 사람들에게 제공하는데 투자하고 있고, 그에 따라 시장에 자극을 주고 있습니다. X선 영상은 폐암과 유방암 검출에 널리 사용되고 있습니다. 또한 컴퓨터 단층촬영(CT) 스캔은 X선에서는 검출되지 않는 폐의 작은 병변을 검출할 수 있습니다. 확인, 진단 및 지원은 의료 분야에서 X선의 다양한 사용법입니다.
- 또한 X선 영상 장비는 골절, 감염증, 다양한 암, 관절염 등의 다양한 질병 검출에도 사용됩니다. 그 결과 이러한 질환과 관련된 증례수 증가는 시장 성장에 플러스 영향을 미칠 가능성이 있습니다. 또한 노인 인구는 관절염에 대해서 매우 취약합니다. 각 환자에 맞추어 진단과 치료를 조정해 결과를 최적화할 수 있는 정밀의료의 미래는 중요한 임상 영역의 지식을 도입하면서, 이종 생물학적(대사, 게놈, 신경 영상 등) 및 임상적 측정의 대규모 데이터세트를 공동으로 분석하는 능력에 의존하고 있습니다. AI의 역할은 이러한 증대하는 요건과 함께 증대할 것으로 예상됩니다.
- 머지 않아 다수의 의료용 영상 처리 장비가 클라우드에 접속되고, AI 알고리즘이 데이터를 분석하고, 인간 의사가 환자를 스크리닝, 평가, 진단하는데 도움이 됩니다. 의료용 영상을 분석하기 위한 AI 구현의 영향은 막대합니다. 멕시코에서는 1억 3,000만명에 대해서 약 4,000명의 방사선과의 밖에 없습니다. 의료용 영상용 AI는 멕시코 등의 국가에서 가장 큰 영향을 미칠 가능성이 있습니다. 2019년 12월 IBM Watson Health는 제105회 RSNA Scientific Assembly and Annual Meeting에서 IBM Watson Health Imaging 인공지능(AI) 플랫폼의 최근 클라이언트와 협업을 강조했습니다. 영국에서 최근 발매된 Clinical Review 3.0은 의료용 영상 연구와 그와 관련된 보고서를 분석하고, 놓칠 가능성 있는 소견을 확인하는 툴이며, 환자의 질 높고 보다 종합적인 케어를 촉진합니다.
- COVID-19 팬데믹은 헬스케어를 포함한 거의 모든 업계를 혼란시켰습니다. 가장 많이 사용되고 있는COVID-19 스크리닝 옵션 중에서 이미징은 단시간에 중요한 진단을 제공하기 때문에 대부분의 헬스케어 전문가에게 선호되고 있습니다. 모든 영상 진단 결과는 바이러스와 다양한 인구통계적 속성의 환자에 대한 영향을 연구하기 위해서 철저하게 사용되고 있습니다. 따라서 의료용 영상용 AI는 더 높은 속도로 성장할 것으로 예상됩니다. 거의 모든 헬스케어 기관이 COVID-19 관리를 개선하고, 그 만연을 막기 위해서 노력하고 있기 때문에 다수의 조직이 의료용 영상 및 영상 분석 툴을 사용해 바이러스 검출과 예방을 개선하고 있습니다.
- 2020년 6월 Johns Hopkins Medicine 팀에 의한 새로운 보고서에 의하면 인공지능은 주로 흉부 영상의 역할을 강화하고, 대규모 데이터를 활용해 COVID-19 검출, 방지 및 치료의 해결책을 빠르게 찾아낼 가능성을 나타내고 있습니다. 팀은 또한 AI는 위험 층별화 개선에도 도움이 될 가능성이 있고, COVID-19 감염 경과에 기반해 환자가 받는 치료 종류에 따라 환자를 분류 가능하다고 언급했습니다. 또한 2020년 8월 국립위생연구소(NIH)는 인공지능과 의료용 영상 기술을 이용해 COVID-19 검출과 치료를 강화하는 의료용 영상 및 데이터 자원 센터(MIDRC)를 출범했습니다.
세계의 의료용 영상용 AI(Medical Imaging AI) 시장을 조사했으며, 시장 개요, 시장 성장 촉진요인 및 저해요인 분석, 시장 기회, Covid-19의 영향, 기술·제공·영상 취득 기술·최종사용자·지역별 시장 규모 추정과 예측, 경쟁 상황, 주요 기업 개요 등 체계적인 정보를 제공합니다.
제2장 조사 방법
제3장 주요 요약
제4장 시장 역학
- 시장 개요
- 시장 추진력
- 이미징 볼륨 증가
- 개별화 치료 능력과 달성 및 환자를 위해 개선된 시술과 치료
- 시장 성장 억제요인
- 업계의 밸류체인 분석
- Porters Five Force 분석
- 신규 참여업체의 위협
- 구매자/소비자의 협상력
- 공급 기업의 협상력
- 대체 제품의 위협
- 경쟁 기업간 경쟁 관계
- 의료용 영상용 AI 시장에 대한 Covid-19의 영향 평가
제5장 기술 현황
제6장 시장 세분화
- 영상 취득 기술별
- 컴퓨터 단층촬영
- 초음파 영상
- 분자 영상
제7장 경쟁 상황
- 기업 개요
- Siemens Healthineers AG
- GE Healthcare
- IBM Watson Health
- BenevolentAI Limited
- Philips Healthcare
- Zebra Medical Vision Inc.
- Samsung Electronics Co. Ltd
- Medtronic Plc
- EchoNous, Inc.
- Enlitic Inc.
- Nvidia Corporation
제8장 투자 분석
제9장 시장 전망
The AI Market in Medical Imaging is expected to register a CAGR of 30.4% over the forecast period from 2021 - 2026. The growing aging population, coupled with rising investment in the healthcare ecosystem, is expected to impact overall market growth over the forecast period positively. Developed nations have been facing this demographic challenge and have been investing in bringing affordable and advanced healthcare systems to the people, thereby providing impetus to the market. X-ray imaging is being widely used to detect lung and breast cancer. Additionally, a computed tomography (CT) scan can detect small lesions in the lungs that go undetected on an x-ray. Confirmative, diagnostic, and supportive are different uses of X-rays in the medical domain.
- Moreover, X-ray imaging equipment is also used to detect diverse diseases, such as fractures, infection, different cancers, and arthritis. As a result, the increasing number of cases associated with these diseases is likely to impact market growth positively. Additionally, the geriatric population is highly vulnerable to arthritis. The future of precision medicine, which allows tailoring diagnosis and treatment to each patient to optimize the outcome, is dependent on the ability to jointly analyze large datasets of heterogeneous biological (e.g., metabolic, genomic, neuroimaging) and clinical measures while incorporating critical clinical domain knowledge. The role of AI is expected to grow with such growing requirements.
- Soon, multiple medical imaging machines will be connected to the cloud, where AI algorithms will analyze the data and help human doctors in screening, assessing, and diagnosing patients. The impact of the implementation of AI to analyze medical images is enormous. In Mexico, there are only about 4,000 radiologists for 130 million people. AI in medical imaging may make the most significant impact in countries such as Mexico. In December 2019, IBM Watson Health highlighted its recent clients and collaborations for its IBM Watson Health Imaging artificial intelligence (AI) platform at the 105th RSNA Scientific Assembly and Annual Meeting. Clinical Review 3.0, a tool recently launched in the United Kingdom that analyzes medical imaging studies and their associated reports to identify potentially missed findings, is facilitating higher quality and more comprehensive care for the patient.
- The COVID-19 pandemic disrupted almost every industry, including healthcare. Among the most used COVID-19 screening options, imaging has been preferred by most of the healthcare professionals, as it provides a crucial diagnosis in a short time. All the imaging results have been used exhaustively to study the virus and its effect on different demography patients. Therefore, AI in Medical Imaging is expected to grow at a higher rate. With almost every healthcare organization putting efforts to manage better and stop the spread of COVID-19, multiple organizations have turned to medical imaging and imaging analytics tools to improve the virus's detection and prevention.
- In June 2020, according to a new report by a team at Johns Hopkins Medicine, artificial intelligence represents the potential, primarily to enhance the role of chest imaging and leveraging large-scale data to quickly find solutions for the detection, containment, and treatment of COVID-19. The team also stated that AI could also help improve risk stratification, categorizing the patients for the type of treatment they receive based on the course of their COVID-19 infection. Moreover, in August 2020, the National Institutes of Health (NIH) launched the Medical Imaging and Data Resource Center (MIDRC), which will utilize the artificial intelligence and medical imaging technology to enhance the COVID-19 detection and treatment.
Key Market Trends
Computed Tomography is Expected to Drive the Market Growth
- The major factors for the growth of the computed tomography (C.T.) market include the growing prevalence of various lifestyle associated chronic diseases such as cancer and cardiovascular conditions and increasing demand for advanced imaging solutions integrated with A.I. and further investment in AI-enabled solutions are some of the factors expected to drive the overall market growth. Increasing demand for advanced assessment tools in the emergency department and a growing number of ambulatory emergency care units are the drivers expected to positively impact the C.T. market growth, which will boost the overall demand of the A.I market in medical imaging.
- In June 2020, Qure.ai announced its first US FDA clearance for its head C.T. scan product. The U.S. Food and Drug Administration's decision covers four critical abnormalities identified by Qure.ai's emergency room product. Now, the A.I. tool can triage radiology scans with intracranial bleeds, mass effect, midline shift, and cranial fractures. Two of these capabilities include cranial fractures and midline shifts, which are exclusive to Qure.ai's product. This means that the recently cleared qER suite will triage nearly all critical abnormalities visible on routine head computed tomography scans.
- Imsight Technology, a Chinese company that has been developing equipment for digital radiographic examinations of the chest since 2018, has devised an A.I. system that assists computer-aided tomographic diagnostic screening of the lungs amid the ongoing coronavirus pandemic. The new system consists of a deep-learning process that reads in a considerable amount of data and can read images accurately as experienced doctors. During a trial in February 2020, the system processed images at more than 99% accuracy.
- According to NCBI, more than 70 million C.T. scans are performed in the U.S. and 5 million in the U.K. every year with an increasing annual rate of 10%, signifying the growth potential of C.T. in the overall medical imaging market. The more extended incubation period of COVID-19 is a massive restriction for early diagnosis and effective treatment for the ongoing pandemic. Preliminary screening of suspected patients by C.T. can reveal lung damages at the early stages. This has a significant impact in the developing countries where tests/million population ratio is lower and is likely to fuel the overall A.I. market in medical imaging.
Asia-Pacific to Witness Highest Growth
- In the Asia Pacific, artificial intelligence in healthcare is expected to witness lucrative growth over the forecast period, owing to rising R&D expenditure and developments in the pharmaceutical and biotechnology sectors. Additionally, the presence of a significant patient pool will trigger demand for better healthcare services, develop healthcare infrastructure, and increase disposable income to support further the growth of AI in Medical Imaging in the region. Furthermore, spending in the healthcare sector gained heightened traction. Economies in the region are increasingly concentrating on developing a robust healthcare infrastructure for patient diagnoses and treatment. According to Invest India, India's hospital sector, accounting for 80% of the total healthcare market, is observing a significant investor interest from both the global and domestic investors.
- Furthermore, AI medical imaging is one of the most common AI applications in the healthcare industry in China. It is currently the second-largest market segment of AI medical applications in China and was predicted to grow at a growth rate of more than 40% and reach a scale of USD 2.5 billion in 2024 (source: Ministry of Foreign Affairs of Denmark). There is a considerable gap in the number of professional doctors in medical imaging in China. The medical imaging dataset increases 30% every year in China, which also accounts for 90% of digital data volume for a hospital. In contrast, the number of radiologists increases by only 4% a year. AI medical imaging in China is considered by industry insiders to be the first market to commercialize AI in the healthcare industry in China.
- Two medical institutions in Shenzhen have currently adopted Imsight's AI system for computer-aided tomographic screening of the lungs. When the system identifies a possible COVID-19 infection, it specifies an affected site and conducts the necessary quantitative data analysis. The spread of COVID-19 has urged medical technology-related companies to shift to commercial production of equipment rapidly. Under normal conditions, companies are centering on activities such as approaching customers. Amid the abrupt increase in demand for medical examinations, new services such as online hospitals, temperature checks by AI, remote medical care, and delivery of drugs via the internet are rapidly moving toward practical use.
- The coronavirus has brought a lot of awareness to the medical industry in South Korea. South Korea has appreciated its fast response and its innovative technologies regarding testing for the coronavirus. The usage of AI in the medical industry in South Korea gained traction in 2019. Korean investors invested a lot of their money into Korean medical startups combining AI technologies into their products and services. Also, universities and corporations in Korea are increasing their partnerships with AI startups in Korea to compete with newer players entering the space. Lunit, a South Korean startup, has developed an AI-based system for detecting pneumonia, often present in COVID patients within seconds.
The AI Market in Medical Imaging is highly competitive, owing to the presence of a large number of players in the market operating in domestic as well as in the international market. The market appears to be moderately fragmented. Owing to the increase in AI applications in the medical imaging market, major players in the market are adopting strategies like product innovation, partnership, mergers, and acquisition. Some of the key developments are:
- July 2020 - Zebra Medical Vision announced that it had entered a strategic collaboration with TELUS Ventures. This collaboration includes an investment expected to grow Zebra-Med's presence in North America and enable the company to showcase its artificial intelligence (AI) solutions to the latest modalities and clinical care settings.
- June 2020 - GE Healthcare introduced its Thoracic Care Suite, a collection of eight artificial intelligence (AI) algorithms from Lunit INSIGHT CXR to help alleviate clinical strain due to COVID-19. The AI suite quickly analyzes chest x-ray findings and flags abnormalities to radiologists for review, including pneumonia, which may indicate COVID-19, as well as tuberculosis, lung nodules, and other radiological findings.
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
TABLE OF CONTENTS
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
- 4.1 Market Overview
- 4.2 Market Drivers
- 4.2.1 Increasing Imaging Volumes
- 4.2.2 Ability and Achievement of Personalized Treatment and Improved Procedures and Treatments for Patients
- 4.3 Market Restraints
- 4.3.1 High Cost and Reluctance of Adoption of These Systems
- 4.4 Industry Value Chain Analysis
- 4.5 Porters Five Force Analysis
- 4.5.1 Threat of New Entrants
- 4.5.2 Bargaining Power of Buyers/Consumers
- 4.5.3 Bargaining Power of Suppliers
- 4.5.4 Threat of Substitute Products
- 4.5.5 Intensity of Competitive Rivalry
- 4.6 Assessment of Impact of Covid-19 on the AI Market in Medical Imaging
5 TECHNOLOGY SNAPSHOT
- 5.1 By Technology
- 5.1.1 Deep Learning
- 5.1.2 Computer Vision
- 5.1.3 NLP
- 5.1.4 Other Technologies
6 MARKET SEGMENTATION
- 6.1 By Offering
- 6.1.1 Software Tools/Platform
- 6.1.2 Services
- 6.2 By Image Acquisition Technology
- 6.2.1 X-Ray
- 6.2.2 Computed Tomography
- 6.2.3 Magnetic Resonance Imaging
- 6.2.4 Ultrasound Imaging
- 6.2.5 Molecular Imaging
- 6.3 By End User
- 6.3.1 Hospitals
- 6.3.2 Clinics
- 6.3.3 Research Laboratories & Diagnostic Centers
- 6.3.4 Other End Users
- 6.4 Geography
- 6.4.1 North America
- 6.4.2 Europe
- 6.4.3 Asia-Pacific
- 6.4.4 Rest of the World
7 COMPETITIVE LANDSCAPE
- 7.1 Company Profiles
- 7.1.1 Siemens Healthineers AG
- 7.1.2 GE Healthcare
- 7.1.3 IBM Watson Health
- 7.1.4 BenevolentAI Limited
- 7.1.5 Philips Healthcare
- 7.1.6 Zebra Medical Vision Inc.
- 7.1.7 Samsung Electronics Co. Ltd
- 7.1.8 Medtronic Plc
- 7.1.9 EchoNous, Inc.
- 7.1.10 Enlitic Inc.
- 7.1.11 Nvidia Corporation
- 7.1.12 Oxipit.ai
8 INVESTMENT ANALYSIS
9 FUTURE OF THE MARKET